These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

302 related articles for article (PubMed ID: 22894958)

  • 21. Efficacy, immunogenicity and safety of a recombinant tetravalent dengue vaccine (CYD-TDV) in children aged 2-17 years: systematic review and meta-analysis.
    Rosa BR; Cunha AJLAD; Medronho RA
    BMJ Open; 2019 Mar; 9(3):e019368. PubMed ID: 30872537
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immunogenicity and safety of one versus two doses of tetravalent dengue vaccine in healthy children aged 2-17 years in Asia and Latin America: 18-month interim data from a phase 2, randomised, placebo-controlled study.
    Sáez-Llorens X; Tricou V; Yu D; Rivera L; Jimeno J; Villarreal AC; Dato E; Mazara S; Vargas M; Brose M; Rauscher M; Tuboi S; Borkowski A; Wallace D
    Lancet Infect Dis; 2018 Feb; 18(2):162-170. PubMed ID: 29122463
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immunogenicity and safety of a tetravalent dengue vaccine and a bivalent HPV vaccine given concomitantly or sequentially in girls aged 9 to 14 years in Mexico.
    Arredondo JL; Villagomez Martinez SM; Concepcion Morales M; Meyer S; Toh ML; Zocchetti C; Vigne C; Mascareñas C
    Vaccine; 2021 Jun; 39(25):3388-3396. PubMed ID: 33992441
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immunogenicity and Safety of a Booster Injection of DTap-IPV//Hib (Pentaxim) Administered Concomitantly With Tetravalent Dengue Vaccine in Healthy Toddlers 15-18 Months of Age in Mexico: A Randomized Trial.
    Melo FIR; Morales JJR; De Los Santos AHM; Rivas E; Vigne C; Noriega F
    Pediatr Infect Dis J; 2017 Jun; 36(6):602-608. PubMed ID: 28067718
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Safety and Immunogenicity of a Tetravalent Dengue Vaccine Candidate in Healthy Children and Adults in Dengue-Endemic Regions: A Randomized, Placebo-Controlled Phase 2 Study.
    Sirivichayakul C; Barranco-Santana EA; Esquilin-Rivera I; Oh HM; Raanan M; Sariol CA; Shek LP; Simasathien S; Smith MK; Velez ID; Wallace D; Gordon GS; Stinchcomb DT
    J Infect Dis; 2016 May; 213(10):1562-72. PubMed ID: 26704612
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tetravalent Dengue Vaccine: A Review in the Prevention of Dengue Disease.
    Scott LJ
    Drugs; 2016 Sep; 76(13):1301-1312. PubMed ID: 27506852
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Live-attenuated, tetravalent dengue vaccine in children, adolescents and adults in a dengue endemic country: randomized controlled phase I trial in the Philippines.
    Capeding RZ; Luna IA; Bomasang E; Lupisan S; Lang J; Forrat R; Wartel A; Crevat D
    Vaccine; 2011 May; 29(22):3863-72. PubMed ID: 21477675
    [TBL] [Abstract][Full Text] [Related]  

  • 28. First Experience of Concomitant Vaccination Against Dengue and MMR in Toddlers.
    Crevat D; Brion JD; Gailhardou S; Laot TM; Capeding MR
    Pediatr Infect Dis J; 2015 Aug; 34(8):884-92. PubMed ID: 25966916
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The Immunogenicity and Safety of CYD-Tetravalent Dengue Vaccine (CYD-TDV) in Children and Adolescents: A Systematic Review.
    Agarwal R; Wahid MH; Yausep OE; Angel SH; Lokeswara AW
    Acta Med Indones; 2017 Jan; 49(1):24-33. PubMed ID: 28450651
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Persistence of Th1/Tc1 responses one year after tetravalent dengue vaccination in adults and adolescents in Singapore.
    Harenberg A; Begue S; Mamessier A; Gimenez-Fourage S; Ching Seah C; Wei Liang A; Li Ng J; Yun Toh X; Archuleta S; Wilder-Smith A; Shek LP; Wartel-Tram A; Bouckenooghe A; Lang J; Crevat D; Caillet C; Guy B
    Hum Vaccin Immunother; 2013 Nov; 9(11):2317-25. PubMed ID: 23839107
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immunogenicity and Safety of Yellow Fever Vaccine (Stamaril) When Administered Concomitantly With a Tetravalent Dengue Vaccine Candidate in Healthy Toddlers at 12-13 Months of Age in Colombia and Peru: A Randomized Trial.
    López P; Lanata CF; Zambrano B; Cortés M; Andrade T; Amemiya I; Terrones C; Gil AI; Verastegui H; Marquez V; Crevat D; Jezorwski J; Noriega F
    Pediatr Infect Dis J; 2016 Oct; 35(10):1140-7. PubMed ID: 27254034
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immunogenicity and Safety of a Tetravalent Dengue Vaccine Administered Concomitantly or Sequentially With Quadrivalent Human Papillomavirus Vaccine in Boys and Girls 9-13 Years of Age in Malaysia: A Phase IIIb, Randomized, Open-label Study.
    Hassan J; Toh TH; Sivapunniam SK; Hasim R; Ghazali NF; Sulaiman S; Koh MT; Meyer S; Toh ML; Zocchetti C; Vigne C; Mascareñas C
    Pediatr Infect Dis J; 2021 Aug; 40(8):774-781. PubMed ID: 34250977
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Secondary Analysis of the Efficacy and Safety Trial Data of the Tetravalent Dengue Vaccine in Children and Adolescents in Colombia.
    Reynales H; Carrasquilla G; Zambrano B; Cortés S M; Machabert T; Jing J; Pallardy S; Haney O; Faccini M; Quintero J; Noriega F
    Pediatr Infect Dis J; 2020 Apr; 39(4):e30-e36. PubMed ID: 32040014
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Lot-to-lot consistency of a tetravalent dengue vaccine in healthy adults in Australia: a randomised study.
    Torresi J; Heron LG; Qiao M; Marjason J; Chambonneau L; Bouckenooghe A; Boaz M; van der Vliet D; Wallace D; Hutagalung Y; Nissen MD; Richmond PC
    Vaccine; 2015 Sep; 33(39):5127-34. PubMed ID: 26279339
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Modelling the immunological response to a tetravalent dengue vaccine from multiple phase-2 trials in Latin America and South East Asia.
    Dorigatti I; Aguas R; Donnelly CA; Guy B; Coudeville L; Jackson N; Saville M; Ferguson NM
    Vaccine; 2015 Jul; 33(31):3746-51. PubMed ID: 26051515
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Safety and Immunogenicity of a Live Attenuated Tetravalent Dengue Vaccine Candidate in Flavivirus-Naive Adults: A Randomized, Double-Blinded Phase 1 Clinical Trial.
    George SL; Wong MA; Dube TJ; Boroughs KL; Stovall JL; Luy BE; Haller AA; Osorio JE; Eggemeyer LM; Irby-Moore S; Frey SE; Huang CY; Stinchcomb DT
    J Infect Dis; 2015 Oct; 212(7):1032-41. PubMed ID: 25791116
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Replication and Excretion of the Live Attenuated Tetravalent Dengue Vaccine CYD-TDV in a Flavivirus-Naive Adult Population: Assessment of Vaccine Viremia and Virus Shedding.
    Torresi J; Richmond PC; Heron LG; Qiao M; Marjason J; Starr-Spires L; van der Vliet D; Jin J; Wartel TA; Bouckenooghe A
    J Infect Dis; 2017 Oct; 216(7):834-841. PubMed ID: 28968794
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immunogenicity and Safety of a Tetravalent Dengue Vaccine Administered Concomitantly or Sequentially With Tdap Vaccine: Randomized Phase IIIb Trial in Healthy Participants 9-60 Years of Age in the Philippines.
    Santos J; Montellano ME; Solante R; Perreras N; Meyer S; Toh ML; Zocchetti C; Vigne C; Mascareñas C
    Pediatr Infect Dis J; 2021 Sep; 40(9):856-863. PubMed ID: 34117198
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Safety and immunogenicity of different doses and schedules of a live attenuated tetravalent dengue vaccine (TDV) in healthy adults: A Phase 1b randomized study.
    Rupp R; Luckasen GJ; Kirstein JL; Osorio JE; Santangelo JD; Raanan M; Smith MK; Wallace D; Gordon GS; Stinchcomb DT
    Vaccine; 2015 Nov; 33(46):6351-9. PubMed ID: 26384447
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy after 1 and 2 doses of CYD-TDV in dengue endemic areas by dengue serostatus.
    Dayan GH; Langevin E; Forrat R; Zambrano B; Noriega F; Frago C; Bouckenooghe A; Machabert T; Savarino S; DiazGranados CA
    Vaccine; 2020 Sep; 38(41):6472-6477. PubMed ID: 32773243
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.